Sandoz Fills Pipeline Gap With EirGenix Trastuzumab Deal

 
• By Aidan Fry

Sandoz has acquired global commercial rights to EirGenix’ Phase III trastuzumab candidate, filling a gap in the Novartis division’s biosimilars pipeline.

Pipeline
Sandoz has filled a gap in its biosimilars portfolio by partnering with EirGenix for trastuzumab • Source: Shutterstock

More from Biosimilars

More from Products